Literature DB >> 26097006

A Light-Controlled TLR4 Agonist and Selectable Activation of Cell Subpopulations.

Lalisa Stutts1, Aaron P Esser-Kahn2.   

Abstract

The spatial and temporal aspects of immune cell signaling are key parameters in defining the magnitude of an immune response. Toll-like receptors (TLRs) on innate immune cells are important in the early detection of pathogens and initiation of an immune response. Controlling the spatial and temporal signaling of TLRs would enable further study of immune synergies and assist in the development of new vaccines. Here, we show a light-based method for the spatial control of TLR4 signaling. A TLR4 agonist, pyrimido[5,4-b]indole, was protected with a cage at a position critical for receptor binding. This afforded a photocontrollable agonist that was inactive while caged, yet effected NF-κB activity in cells following UV photocontrolled deprotection. We demonstrated spatial control of NF-κB activation within a population of cells by treating all cells with the caged TLR4 agonist and constraining light exposure and consequent activation to a region of interest.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cage compound; immune agents; immunology; receptors; signal transduction

Mesh:

Substances:

Year:  2015        PMID: 26097006      PMCID: PMC4881745          DOI: 10.1002/cbic.201500164

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  32 in total

1.  Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex.

Authors:  K Ohashi; V Burkart; S Flohé; H Kolb
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

2.  Modulating the innate immune response by combinatorial engineering of endotoxin.

Authors:  Brittany D Needham; Sean M Carroll; David K Giles; George Georgiou; Marvin Whiteley; M Stephen Trent
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-07       Impact factor: 11.205

3.  Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4.

Authors:  Alexzander Asea; Michael Rehli; Edith Kabingu; Jason A Boch; Olivia Bare; Philip E Auron; Mary Ann Stevenson; Stuart K Calderwood
Journal:  J Biol Chem       Date:  2002-02-08       Impact factor: 5.157

4.  The molecular basis of the host response to lipopolysaccharide.

Authors:  Clare E Bryant; David R Spring; Monique Gangloff; Nicholas J Gay
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

5.  Pulsatile stimulation determines timing and specificity of NF-kappaB-dependent transcription.

Authors:  Louise Ashall; Caroline A Horton; David E Nelson; Pawel Paszek; Claire V Harper; Kate Sillitoe; Sheila Ryan; David G Spiller; John F Unitt; David S Broomhead; Douglas B Kell; David A Rand; Violaine Sée; Michael R H White
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

6.  Structure-activity relationship of synthetic toll-like receptor 4 agonists.

Authors:  Axel G Stöver; Jean Da Silva Correia; Jay T Evans; Christopher W Cluff; Mark W Elliott; Eric W Jeffery; David A Johnson; Michael J Lacy; Jory R Baldridge; Peter Probst; Richard J Ulevitch; David H Persing; Robert M Hershberg
Journal:  J Biol Chem       Date:  2003-10-21       Impact factor: 5.157

7.  Evidence that opioids may have toll-like receptor 4 and MD-2 effects.

Authors:  Mark R Hutchinson; Yingning Zhang; Mitesh Shridhar; John H Evans; Madison M Buchanan; Tina X Zhao; Peter F Slivka; Benjamen D Coats; Niloofar Rezvani; Julie Wieseler; Travis S Hughes; Kyle E Landgraf; Stefanie Chan; Stephanie Fong; Simon Phipps; Joseph J Falke; Leslie A Leinwand; Steven F Maier; Hang Yin; Kenner C Rice; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2009-08-11       Impact factor: 7.217

8.  Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands.

Authors:  Michael Chan; Tomoko Hayashi; Richard D Mathewson; Afshin Nour; Yuki Hayashi; Shiyin Yao; Rommel I Tawatao; Brian Crain; Igor F Tsigelny; Valentina L Kouznetsova; Karen Messer; Minya Pu; Maripat Corr; Dennis A Carson; Howard B Cottam
Journal:  J Med Chem       Date:  2013-05-24       Impact factor: 7.446

9.  A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.

Authors:  Rhea N Coler; Susan L Baldwin; Narek Shaverdian; Sylvie Bertholet; Steven J Reed; Vanitha S Raman; Xiuhua Lu; Joshua DeVos; Kathy Hancock; Jacqueline M Katz; Thomas S Vedvick; Malcolm S Duthie; Christopher H Clegg; Neal Van Hoeven; Steven G Reed
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

10.  Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Authors:  Rhea N Coler; Sylvie Bertholet; Magdalini Moutaftsi; Jeff A Guderian; Hillarie Plessner Windish; Susan L Baldwin; Elsa M Laughlin; Malcolm S Duthie; Christopher B Fox; Darrick Carter; Martin Friede; Thomas S Vedvick; Steven G Reed
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

View more
  4 in total

1.  Controlling the Oligomerization State of Aβ-Derived Peptides with Light.

Authors:  Patrick J Salveson; Sepehr Haerianardakani; Alexander Thuy-Boun; Adam G Kreutzer; James S Nowick
Journal:  J Am Chem Soc       Date:  2018-04-20       Impact factor: 15.419

2.  Spatially resolved microfluidic stimulation of lymphoid tissue ex vivo.

Authors:  Ashley E Ross; Maura C Belanger; Jacob F Woodroof; Rebecca R Pompano
Journal:  Analyst       Date:  2016-11-30       Impact factor: 4.616

3.  Surface Coating of Nanoparticles Reduces Background Inflammatory Activity while Increasing Particle Uptake and Delivery.

Authors:  Brittany A Moser; Rachel C Steinhardt; Aaron P Esser-Kahn
Journal:  ACS Biomater Sci Eng       Date:  2016-12-01

4.  Conditionally Controlling Human TLR2 Activity via Trans-Cyclooctene Caged Ligands.

Authors:  Michel J van de Graaff; Timo Oosenbrug; Mikkel H S Marqvorsen; Clarissa R Nascimento; Mark A R de Geus; Bénédicte Manoury; Maaike E Ressing; Sander I van Kasteren
Journal:  Bioconjug Chem       Date:  2020-06-08       Impact factor: 4.774

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.